Traws Pharma, Inc.
TRAW
$2.16
-$0.32-12.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,159.29% | 1,184.51% | 0.44% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,159.29% | 1,184.51% | 0.44% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,159.29% | 1,184.51% | 0.44% | 0.00% | 0.00% |
| SG&A Expenses | -11.31% | 12.85% | 13.06% | 35.13% | 20.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.39% | 11.00% | 28.21% | 22.47% | 11.58% |
| Operating Income | 34.49% | 1.85% | -28.53% | -22.72% | -11.70% |
| Income Before Tax | 90.55% | 87.00% | -671.37% | -778.84% | -597.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.55% | 87.00% | -671.37% | -778.84% | -597.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.55% | 87.00% | -671.37% | -778.84% | -597.51% |
| EBIT | 34.49% | 1.85% | -28.53% | -22.72% | -11.70% |
| EBITDA | 34.53% | 1.79% | -28.60% | -22.76% | -11.72% |
| EPS Basic | 177.60% | 166.85% | 142.85% | 78.24% | -51.63% |
| Normalized Basic EPS | 69.83% | 25.04% | 8.71% | -27.27% | 0.33% |
| EPS Diluted | 177.38% | 166.66% | 142.61% | 78.23% | -51.17% |
| Normalized Diluted EPS | 69.38% | 24.53% | 8.22% | -27.27% | 0.33% |
| Average Basic Shares Outstanding | 521.51% | 337.04% | 266.95% | 84.94% | 18.40% |
| Average Diluted Shares Outstanding | 527.78% | 343.51% | 274.36% | 84.94% | 18.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |